サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1439995

がん治療薬 - 世界市場の考察、競合情勢、市場予測（2030年）

Oncology Drugs - Market Insights, Competitive Landscape, and Market Forecast - 2030
出版日: 受注後更新 | 発行: DelveInsight | ページ情報: 英文 150 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
がん治療薬 - 世界市場の考察、競合情勢、市場予測（2030年）
出版日: 受注後更新
発行: DelveInsight
ページ情報: 英文 150 Pages
納期: 2～10営業日
ご注意事項 :
本レポートの納品は、最新情報反映のため受注時に適宜更新しお届けいたします。
更新情報の反映作業にあたり納期もレポート毎に異なりますので、ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界のがん治療薬の市場規模は、2023年に1,799億6,000万米ドル、2030年までに3,682億2,000万米ドルに達し、2024年～2030年の予測期間にCAGRで12.74％の成長が見込まれます。市場は、2022年にがん関連死亡者数とがん罹患者数の最多を占めた肺がんなどのさまざまながんの流行や、前立腺がんや乳がんなど特定のがん種では年齢が発症に重要な役割を果たすことから、老年人口の増加といった要因の存在により、積極的な市場成長を示しています。さらに、より顕著な治療効果をもたらすCAR-T細胞療法のような標的療法の開発に注目が集まっており、新製品ががん治療薬として規制当局の承認を得ていることが、がん治療薬市場をさらに牽引しています。

がん治療薬の市場力学

がん治療薬市場の主な促進要因の1つは、がん罹患率の急増です。International Agency for Researchが実施したGLOBOCAN調査によると、2020年に世界で1,930万人の新規がん患者と約1,000万人のがん死亡が報告されたと推定されています。また、上記の資料によれば、2020年に肺がんがもっとも多く、次いで前立腺がん（14.1％）、大腸がん（10.6％）、胃がん（7.1％）、肝臓がん（6.3％）と続きます。がんは身体を衰弱させる疾患であるため、がん細胞を治療するには大規模な治療が必要となります。すべてのがんに治療が必要なわけではありませんが、ほとんどのがんに治療が必要です。化学療法、遺伝子治療、免疫療法などのさまざまな治療法ががん治療に採用されているのは、がん治療において治癒効果だけでなく緩和効果も得られるという利点があるからです。このように、さまざまな種類のがん治療薬に対するニーズが高まっているのは、さまざまな種類の治療に反応する可能性のあるがんの罹患率の増加によるものと考えられます。したがって、前述のすべての要因が、がん治療薬に対する需要の増加に寄与し、結果として世界のがん治療薬市場の成長を後押しすると予測されます。

がん罹患率の増加を考慮し、製薬企業の多くはがん領域における広範な研究開発活動に注力しています。その結果、より多くの製品が市場に投入されるようになっています。例えば、米国食品医薬品局（FDA）は、慢性リンパ性白血病におけるBRUKINSA（ザヌブルチニブ）の新薬追加申請を承認しました。別の例では、米国FDAは2022年5月、Johnson & Johnsonの輸液療法Rybrevantを、上皮成長因子と呼ばれるがんタンパク質に特定の変異を有する非小細胞肺がんの治療薬として承認しました。

しかし、骨量の減少などのさまざまながん治療に伴う潜在的な副作用や、特に中低所得国におけるがん治療薬のコストが、がん治療薬市場の成長にとっての課題となる可能性があります。

がん治療薬市場は、COVID-19の拡大を抑制するための対策の実施によってマイナスの影響を受けました。COVID-19パンデミックによって生じた緊急事態に対応するため、その他のすべての医療専門分野では患者数の減少が見られました。例えば、Cancer Research UKによると、英国だけで、緊急の肺がん紹介は最初のロックダウン期間に75％まで減少しました。これは症例の減少とは関係なく、緊急に必要な診断を求め、それを得る人が減ったということです。残念ながら、こうした動向は世界各国で顕著でした。とはいえ、がん医療を変革する戦略の考案により、がん治療薬市場は回復基調にあり、それによって2024年～2030年の予測期間にがん治療薬市場の将来の見通しが示されます。

がん治療薬市場のセグメント分析

がん治療薬市場の治療タイプセグメントでは、標的療法カテゴリが予測期間（2024年～2030年）に市場で突出した収益シェアを占めると推定されます。これは、標的療法に関連する利点に起因しています。標的とするタンパク質や遺伝子に特異性があり、がん細胞の除去という点で予後が良好であることから、標的療法はがんの治療オプションとして好まれています。がん細胞に関連する重要な特徴の1つは、免疫システムのチェックポイントを回避する能力です。標的療法は、がん細胞を標的にすることで、免疫システムによる識別を可能にし、それによって破壊を助けます。

当レポートでは、世界のがん治療薬市場について調査分析し、市場規模と予測、促進要因と課題、企業と製品のプロファイルなどを提供しています。

目次

第1章 がん治療薬市場レポートのイントロダクション

第2章 がん治療薬市場のエグゼクティブサマリー

  • 調査範囲
  • 市場の概要
  • 競争力の評価
  • 財務ベンチマーク

第3章 規制と特許の分析

  • 米国
  • 欧州
  • 日本
  • 中国

第4章 がん治療薬市場の主な要因の分析

  • がん治療薬市場の促進要因
  • がん治療薬市場の抑制要因と課題
  • がん治療薬市場の機会

第5章 がん治療薬市場のポーターのファイブフォース分析

第6章 がん治療薬市場に対するCOVID-19の影響分析

第7章 がん治療薬市場情勢

  • 治療タイプ別
    • 化学療法
    • ホルモン療法
    • 標的療法
    • その他
  • がんタイプ別
    • 乳がん
    • 肺がん
    • 前立腺がん
    • 血液がん
  • エンドユーザー別
    • 病院
    • 専門クリニック
  • 地域
    • 北米
    • 欧州
    • アジア太平洋
    • その他の地域

第8章 がん治療薬市場における：世界の企業シェア分析 - 主要3～5社

第9章 がん治療薬市場の企業と製品のプロファイル

  • GlaxoSmithKline
  • Eli Lilly & Company
  • F. Hoffmann-La Roche Ltd
  • AbbVie Inc.
  • Amgen Inc.
  • Sanofi
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • AstraZeneca
  • Bristol Myers Squibbs
  • Gilead Sciences, Inc.
  • Janssen Global Services, LLC
  • BAYER AG
  • Celldex Therapeutics Inc
  • Alaunos Therapeutics, Inc.
  • Astellas Pharma Inc
  • Genentech Inc
  • Sandoz International GmbH
  • BeiGene

第10章 KOLの見解

第11章 プロジェクトアプローチ

第12章 DelveInsightについて

第13章 免責事項とお問い合わせ

図表

List of Tables

  • Table 1: Competitive Analysis
  • Table 2: COVID-19 Impact Analysis on Oncology Drugs Market
  • Table 3: Oncology Drugs Market in Global (2021-2030)
  • Table 4: Oncology Drugs Market in Global by Therapy Type (2021-2030)
  • Table 5: Oncology Drugs Market in Global by Cancer Type (2021-2030)
  • Table 6: Oncology Drugs Market in Global by End User (2021-2030)
  • Table 7: Oncology Drugs Market in Global by Geography (2021-2030)
  • Table 8: Oncology Drugs Market in North America (2021-2030)
  • Table 9: Oncology Drugs Market in North America by Country (2021-2030)
  • Table 10: Oncology Drugs Market in the US (2021-2030)
  • Table 11: Oncology Drugs Market in Canada (2021-2030)
  • Table 12: Oncology Drugs Market in Mexico (2021-2030)
  • Table 13: Oncology Drugs Market in Europe (2021-2030)
  • Table 14: Oncology Drugs Market in Europe by Country (2021-2030)
  • Table 15: Oncology Drugs Market in France (2021-2030)
  • Table 16: Oncology Drugs Market in Germany (2021-2030)
  • Table 17: Oncology Drugs Market in the United Kingdom (2021-2030)
  • Table 18: Oncology Drugs Market in Italy (2021-2030)
  • Table 19: Oncology Drugs Market in Spain (2021-2030)
  • Table 20: Oncology Drugs Market in Russia (2021-2030)
  • Table 21: Oncology Drugs Market in Rest of Europe (2021-2030)
  • Table 22: Oncology Drugs Market in APAC (2021-2030)
  • Table 23: Oncology Drugs Market in APAC by Country (2021-2030)
  • Table 24: Oncology Drugs Market in China (2021-2030)
  • Table 25: Oncology Drugs Market in Japan (2021-2030)
  • Table 26: Oncology Drugs Market in India (2021-2030)
  • Table 27: Oncology Drugs Market in Australia (2021-2030)
  • Table 28: Oncology Drugs Market in South Korea (2021-2030)
  • Table 29: Oncology Drugs Market in Rest of APAC (2021-2030)
  • Table 30: Oncology Drugs Market in Rest of World (2021-2030)
  • Table 31: Oncology Drugs Market in RoW by Region (2021-2030)
  • Table 32: Oncology Drugs Market in Middle East (2021-2030)
  • Table 33: Oncology Drugs Market in Africa (2021-2030)
  • Table 34: Oncology Drugs Market in South America (2021-2030)

List of Figures

  • Figure 1: Competitive Analysis
  • Figure 2: COVID-19 Impact Analysis on Oncology Drugs Market
  • Figure 3: Oncology Drugs Market in Global (2021-2030)
  • Figure 4: Oncology Drugs Market in Global by Therapy Type (2021-2030)
  • Figure 5: Oncology Drugs Market in Global by Cancer Type (2021-2030)
  • Figure 6: Oncology Drugs Market in Global by End User (2021-2030)
  • Figure 7: Oncology Drugs Market in Global by Geography (2021-2030)
  • Figure 8: Oncology Drugs Market in North America (2021-2030)
  • Figure 9: Oncology Drugs Market in North America by Country (2021-2030)
  • Figure 10: Oncology Drugs Market in the US (2021-2030)
  • Figure 11: Oncology Drugs Market in Canada (2021-2030)
  • Figure 12: Oncology Drugs Market in Mexico (2021-2030)
  • Figure 13: Oncology Drugs Market in Europe (2021-2030)
  • Figure 14: Oncology Drugs Market in Europe by Country (2021-2030)
  • Figure 15: Oncology Drugs Market in France (2021-2030)
  • Figure 16: Oncology Drugs Market in Germany (2021-2030)
  • Figure 17: Oncology Drugs Market in the United Kingdom (2021-2030)
  • Figure 18: Oncology Drugs Market in Italy (2021-2030)
  • Figure 19: Oncology Drugs Market in Spain (2021-2030)
  • Figure 20: Oncology Drugs Market in Russia (2021-2030)
  • Figure 21: Oncology Drugs Market in Rest of Europe (2021-2030)
  • Figure 22: Oncology Drugs Market in APAC (2021-2030)
  • Figure 23: Oncology Drugs Market in APAC by Country (2021-2030)
  • Figure 24: Oncology Drugs Market in China (2021-2030)
  • Figure 25: Oncology Drugs Market in Japan (2021-2030)
  • Figure 26: Oncology Drugs Market in India (2021-2030)
  • Figure 27: Oncology Drugs Market in Australia (2021-2030)
  • Figure 28: Oncology Drugs Market in South Korea (2021-2030)
  • Figure 29: Oncology Drugs Market in Rest of APAC (2021-2030)
  • Figure 30: Oncology Drugs Market in Rest of World (2021-2030)
  • Figure 31: Oncology Drugs Market in RoW by Region (2021-2030)
  • Figure 32: Oncology Drugs Market in Middle East (2021-2030)
  • Figure 33: Oncology Drugs Market in Africa (2021-2030)
  • Figure 34: Oncology Drugs Market in South America (2021-2030)
  • Figure 35: Market Drivers
  • Figure 36: Market Barriers
  • Figure 37: Marker Opportunities
  • Figure 38: PORTER'S Five Force Analysis
目次
Product Code: DISR0032

Oncology Drugs Market By Therapy Type (Chemotherapy, Hormonal Therapy, Targeted Therapy [Gene Therapy And Immunotherapy], And Others), By Cancer Type (Breast Cancer, Lung Cancer, Prostate Cancer, Blood Cancers, And Others), By End User (Hospitals, Specialty Clinics, And Others), and by geography is estimated to grow at a healthy CAGR forecast till 2030 due to rising prevalence of various cancers such as lung and breast cancers and growing demand for targeted therapies for cancer treatment

Global oncology drugs market was valued at USD 179.96 Billion in 2023, growing at a CAGR of 12.74% during the forecast period from 2024 to 2030, in order to reach USD 368.22 Billion by 2030. The oncology drugs market is witnessing a positive market growth owing to the factors such as rising prevalence of various cancers such as lung cancer which accounted for the highest number of cancer-related deaths and highest cancer incidence in 2022, and presence of factors such as growth in aging population wherein age plays a key role in cancer development in certain cancer types such as prostate and breast cancers. Moreover, the growing focus on developing targeted therapies such as CAR-T cell therapies to provide a more pronounced therapeutic effect is further driving the oncology drugs market as new products are gaining regulatory approvals for cancer treatment.

Oncology Drugs Market Dynamics:

One of the key aspects driving the oncology drugs market can be attributed to the surge in cancer incidence. The GLOBOCAN study conducted by the International Agency for Research on Cancer mentioned that in 2020, an estimated number of 19.3 million new cancer cases (18.1 million excluding non-melanoma skin cancer) and approximately 10.0 million cancer deaths were reported globally. The source mentioned above also stated that in 2020, lung cancer was the main cause accounting for the highest number (1.4 million) of cases followed by prostate (14.1%), colorectum (10.6%), stomach (7.1%), and liver (6.3%) cancers. Cancer, being a debilitating disease, requires extensive treatment in order to treat cancerous cells. Even though not all cancer would require treatment, most of them do. Various therapies such as chemotherapy, gene therapy, and immunotherapy are employed in cancer treatment due to the benefits associated with them in terms of providing curative as well as palliative effect in cancer treatment. Thus, the growing need for oncology drugs of various types can be attributed to the increasing cancer incidence which may respond to different therapy types. Therefore, all the aforementioned factors are projected to contribute to the growing demand for oncology drugs, ultimately boosting the growth of the global oncology drugs market.

Considering the increasing incidence of cancers, most of the pharmaceutical companies are focusing on extensive research and development activities in the oncology domain. This has resulted in more products being launched in the market. For instance, the US Food and Drug Administration (FDA) granted the regulatory approval for their supplemental new drug application for BRUKINSA (zanubrutinib) in Chronic Lymphocytic Leukemia. In another example, in May 2022, the US FDA approved Johnson & Johnson's infused therapy Rybrevant for the treatment of non-small cell lung cancer with a certain mutation to a cancer protein called epidermal growth factor.

However, potential side-effects associated with different cancer therapies such as loss of bone mass and cost of oncology drugs especially in low- and middle-income countries may prove to be challenging factors for oncology drugs market growth.

The oncology drugs market was negatively impacted by the implementation of measures to curb the spread of the COVID-19 infection. In order to cater to the exigency created by the COVID-19 pandemic, all other medical specialties witnessed a reduction in patient load. For instance, according to Cancer Research UK, in the UK alone, urgent lung cancer referrals fell up to 75% during the first lockdown. This did not correlate to the decrease in cases, but that fewer people sought and obtained the diagnosis they urgently needed. Unfortunately, these trends were prominent across countries around the globe. Nevertheless, the market for oncology drugs is on a period of recovery owing to devising of strategies to transform cancer care thereby presenting a future outlook for oncology drugs market during the forecast period from 2024-2030.

Oncology Drugs Market Segment Analysis:

Oncology Drugs Market by Therapy Type (Chemotherapy, Hormonal Therapy, Targeted Therapy [Gene Therapy and Immunotherapy], and Others), by Cancer Type (Breast Cancer, Lung Cancer, Prostate Cancer, Blood Cancers, and Others), by End User (Hospitals, Specialty Clinics, and Others), and by Geography (North America, Europe, Asia-Pacific, and Rest of the World)

In the therapy type segment of the oncology drugs market, the targeted therapy category is estimated to account for a prominent revenue share in market during the forecast period (2024-2030). This can be attributed to the advantages associated with targeted therapy. Owing to its specificity in targeting proteins and genes of interest and providing better prognostic outcomes in terms of eliminating cancer cells, targeted therapy is being preferred as the choice of treatment in oncology. One of the key aspects associated with cancer cells is the ability to evade immune system checkpoints; targeted therapy helps in marking cancer cells enabling in their identification by the immune system thereby helping in their destruction.

Considering the advantages associated with targeted therapy, there are currently over 900 applications with the US Food and Drug Administration to investigate gene therapy in clinical trials. This has also resulted in an increased number of product approvals in the market. For instance, in March 2022, the US FDA approved the idecabtagene vicleucel (Abecma) for the treatment of multiple myeloma in patients with relapsed or treatment-resistant myeloma.

Thus, owing to the factors stated above, this therapy category is expected to witness a considerable growth eventually contributing the overall growth of the global oncology drugs market in the forecast period.

North America is expected to dominate the overall Oncology Drugs Market:

Among all the regions, North America is estimated to amass the largest revenue share in the global oncology drugs market. This can be ascribed to the high prevalence of cancers, and a supportive regulatory environment among other factors in the region. Furthermore, high disposable income, sophisticated healthcare infrastructure, and increased awareness regarding new treatments coupled with extensive insurance coverage for these treatments are also expected to aid in the oncology drugs market growth in this region.

One of the key supporting factors for the growth of the North America oncology drugs market is the increasing prevalence of cancers in the United States. As per the figures mentioned by the American Cancer Society, in 2022, it was estimated that 1.9 million new cancer cases would have been diagnosed in the United States. The data provided by the Centers for Disease Control and Prevention (2023), in 2018, 1,708,921 new cases of cancers were reported. For instance, the American Cancer Society estimates that in 2022, approximately 287,850 new cases of invasive breast cancer are expected to be diagnosed in women in the United States. Therefore, the increasing incidence of cancers such as breast cancer along with other cancer types in the country is expected to further drive the demand for oncology drugs thereby contributing in the growth of the United States oncology drugs market along with the overall growth of the North America oncology drugs market.

Furthermore, as the demand for targeted therapies in cancer treatment is witnessing an increase, there has been a major focus on extensive research and development in translation research leading to the development of new therapies as well as product approvals for the same. For instance, in September 2022, Health Canada approved LUMAKRAS(TM) (sotorasib) - the first and only targeted treatment for patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer. Similarly, in May 2020, the US Food and Drug Administration granted regulatory approval for the treatment of adult patients with non-small cell lung cancer (NSCLC) that has spread to other parts of the body.

Thus, such product development activities along with other contributing factors such as the presence of a robust healthcare system and insurance coverage are further driving the demand for oncology drugs in the North American region.

Oncology Drugs Market Key Players:

Some of the key market players operating in the oncology drugs market includes GlaxoSmithKline, Eli Lilly & Company, F. Hoffmann-La Roche Ltd, AbbVie Inc., Amgen Inc., Sanofi, Merck & Co., Inc, Novartis AG, Pfizer Inc, AstraZeneca, Bristol Myers Squibb., Gilead Sciences, Inc., Janssen Global Services, LLC, BAYER AG., Celldex Therapeutics Inc., Alaunos Therapeutics, Inc., Astellas Pharma Inc., Genentech, Inc., Sandoz International GmbH, and BeiGene others.

Recent Developmental Activities in Oncology Drugs Market:

In October 15, 2022, the US FDA approved atezolizumab (Tecentriq) by Genentech, Inc. for adjuvant treatment following resection and platinum-based chemotherapy in patients with stage II to IIIA non-small cell lung cancer (NSCLC).

In August 2022, Bristol Myers Squibbs received the conditional marketing authorization for Abecma (idecabtagene vicleucel) by the European Commission for the treatment of adult patients with relapsed and refractory multiple myeloma. It is a first-in-class B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T cell immunotherapy.

In April 2022, Sanofi announced the acquisition of Tidal Therapeutics which is involved in the development of mRNA-based research platform. This acquisition will help Sanofi utilize this technology platform to expand their capabilities in the field of immunology and oncology.

Key Takeaways from the Oncology Drugs Market Report Study

  • Market size analysis for current oncology drugs market size (2023), and market forecast for 5 years (2024-2030)
  • The effect of the COVID-19 pandemic on this market is significant. To capture and analyze suitable indicators, our experts are closely watching the oncology drugs market.
  • Top key product/services/technology developments, merger, acquisition, partnership, joint venture happened for last 3 years
  • Key companies dominating the global oncology drugs market.
  • Various opportunities available for the other competitors in the oncology drugs market space.
  • What are the top performing segments in 2023? How these segments will perform in 2030.
  • Which is the top-performing regions and countries in the current oncology drugs market scenario?
  • Which are the regions and countries where companies should have concentrated on opportunities for oncology drugs market growth in the coming future?

Target Audience who can be benefited from this Oncology Drugs Market Report Study

  • Oncology drugs products providers
  • Research organizations and consulting companies
  • Oncology drugs -related organizations, associations, forums, and other alliances
  • Government and corporate offices
  • Start-up companies, venture capitalists, and private equity firms
  • Distributors and Traders dealing in oncology drugs
  • Various End-users who want to know more about the oncology drugs market and latest technological developments in the oncology drugs market.

Frequently Asked Questions for Oncology Drugs Market:

1. What is Oncology Drugs?

Oncology drugs encompasses all kinds of cancer treatments such as chemotherapy, radiation therapy, hormonal therapy and targeted therapy among others that aim to kill cancer cells to provide therapeutic effect.

2. What is the global market for Oncology Drugs?

Global oncology drugs market was valued at USD 179.96 Billion in 2023, growing at a CAGR of 12.74% during the forecast period from 2024 to 2030, in order to reach USD 368.22 Billion by 2030.

3. What are the drivers for Global Oncology Drugs Market?

The oncology drugs market is witnessing a positive market growth owing to the factors such as rising prevalence of rising prevalence of cancers such as lung cancer which are contributing in the growing demand for cancer treatment, and presence of factors such as increasing aging population wherein age plays a key role in cancer development in certain cancer types such as breast cancer. Moreover, the growing focus on developing targeted therapies to provide a more pronounced therapeutic effect is further driving the oncology drugs market as new products are gaining regulatory approvals for cancer treatment.

4. Who are the key players operating in Global Oncology Drugs Market?

Some of the key market players operating in the oncology drugs market includes GlaxoSmithKline, Eli Lilly & Company, F. Hoffmann-La Roche Ltd, AbbVie Inc., Amgen Inc, Sanofi, Merck & Co., Inc, Novartis AG, Pfizer Inc, AstraZeneca, Bristol Myers Squibb., Gilead Sciences, Inc., Janssen Global Services, LLC, BAYER AG., Celldex Therapeutics Inc., Alaunos Therapeutics, Inc., Astellas Pharma Inc., Genentech, Inc., Sandoz International GmbH, and BeiGene others.

5. Which region has the highest share in Oncology Drugs Market?

North America is expected to hold the highest share in the revenue in the Oncology Drugs market during the forecast period. This can be ascribed to the high prevalence of cancers, and a supportive regulatory environment among other factors in the region. Furthermore, high disposable income, sophisticated healthcare infrastructure, and increased awareness regarding new treatments coupled with extensive insurance coverage for these treatments are also expected to aid in the oncology drugs market growth in this region.

Table of Contents

1.Oncology Drugs Market Report Introduction

2.Oncology Drugs Market Executive Summary

  • 2.1. Scope of the Study
  • 2.2. Market at Glance
  • 2.3. Competitive Assessment
  • 2.4. Financial Benchmarking

3. Regulatory and Patent Analysis

  • 3.1. The United States
  • 3.2. Europe
  • 3.3. Japan
  • 3.4. China

4. Oncology Drugs Market Key Factors Analysis

  • 4.1. Oncology Drugs Market Drivers
    • 4.1.1. Increasing Incidence of Various Cancers
    • 4.1.2. Rise in External Factors Contributing in Cancer Development
    • 4.1.3. Growing Popularity of Precision Medicine and Targeted Therapy
    • 4.1.4. Technological Advancements in Product Development
  • 4.2. Oncology Drugs Market Restraints and Challenges
    • 4.2.1. Potential Side-Effects Associated with Cancer Therapies
    • 4.2.2. High Cost of Oncology Drugs
  • 4.3. Oncology Drugs Market Opportunities
    • 4.3.1. Improving Affordability of Cancer Therapies
    • 4.3.2. Development of Safer Cancer Therapies with Minimal Side-Effects

5. Oncology Drugs Market Porter's Five Forces Analysis

  • 5.1. Bargaining Power of Suppliers
  • 5.2. Bargaining Power of Consumers
  • 5.3. Threat of New Entrants
  • 5.4. Threat of Substitutes
  • 5.5. Competitive Rivalry

6. COVID-19 Impact Analysis on Oncology Drugs Market

7. Oncology Drugs Market Layout

  • 7.1. By Therapy Type
    • 7.1.1. Chemotherapy
    • 7.1.2. Hormonal Therapy
    • 7.1.3. Targeted Therapy
      • 7.1.3.1. Gene Therapy
      • 7.1.3.2. Immunotherapy
    • 7.1.4. Others
  • 7.2. By Cancer Type
    • 7.2.1. Breast Cancer
    • 7.2.2. Lung Cancer
    • 7.2.3. Prostate Cancer
    • 7.2.4. Blood Cancers
    • 7.2.5. Others
  • 7.3. By End User
    • 7.3.1. Hospitals
    • 7.3.2. Specialty Clinics
    • 7.3.3. Others
  • 7.4. By Geography
    • 7.4.1. North America
      • 7.4.1.1. North America Oncology Drugs Market, by Country
      • 7.4.1.4.1. United States
      • 7.4.1.4.2. Canada
      • 7.4.1.4.3. Mexico
    • 7.4.2. Europe
      • 7.4.2.1. Europe Oncology Drugs Market, by Country
      • 7.4.2.4.1. France
      • 7.4.2.4.2. Germany
      • 7.4.2.4.3. United Kingdom
      • 7.4.2.4.4. Italy
      • 7.4.2.4.5. Spain
      • 7.4.2.2.6. Russia
      • 7.4.2.2.7. Rest of Europe
    • 7.4.3. Asia-Pacific
      • 7.4.3.1. Asia-Pacific Oncology Drugs Market, by Country
      • 7.4.3.4.1. China
      • 7.4.3.4.2. Japan
      • 7.4.3.4.3. India
      • 7.4.3.4.4. Australia
      • 7.4.3.4.5. South Korea
      • 7.4.3.4.6. Rest of Asia Pacific
    • 7.4.4. Rest of the World (RoW)
      • 7.4.4.1. RoW Oncology Drugs Market, by Region
      • 7.4.4.4.1. Middle East
      • 7.4.4.4.2. Africa
      • 7.4.4.4.3. South America

8. Oncology Drugs Market Global Company Share Analysis - Key 3-5 Companies

9. Oncology Drugs Market Company and Product Profiles

  • 9.1. GlaxoSmithKline
    • 9.1.1. Company Overview
    • 9.1.2. Company Snapshot
    • 9.1.3. Financial Overview
    • 9.1.4. Product Listing
    • 9.1.5. Entropy
  • 9.2. Eli Lilly & Company
    • 9.2.1. Company Overview
    • 9.2.2. Company Snapshot
    • 9.2.3. Financial Overview
    • 9.2.4. Product Listing
    • 9.2.5. Entropy
  • 9.3. F. Hoffmann-La Roche Ltd,
    • 9.3.1. Company Overview
    • 9.3.2. Company Snapshot
    • 9.3.3. Financial Overview
    • 9.3.4. Product Listing
    • 9.3.5. Entropy
  • 9.4. AbbVie Inc.
    • 9.4.1. Company Overview
    • 9.4.2. Company Snapshot
    • 9.4.3. Financial Overview
    • 9.4.4. Product Listing
    • 9.4.5. Entropy
  • 9.5. Amgen Inc.
    • 9.5.1. Company Overview
    • 9.5.2. Company Snapshot
    • 9.5.3. Financial Overview
    • 9.5.4. Product Listing
    • 9.5.5. Entropy
  • 9.6. Sanofi
    • 9.6.1. Company Overview
    • 9.6.2. Company Snapshot
    • 9.6.3. Financial Overview
    • 9.6.4. Product Listing
    • 9.6.5. Entropy
  • 9.7. Merck & Co., Inc.
    • 9.7.1. Company Overview
    • 9.7.2. Company Snapshot
    • 9.7.3. Financial Overview
    • 9.7.4. Product Listing
    • 9.7.5. Entropy
  • 9.8. Novartis AG
    • 9.8.1. Company Overview
    • 9.8.2. Company Snapshot
    • 9.8.3. Financial Overview
    • 9.8.4. Product Listing
    • 9.8.5. Entropy
  • 9.9. Pfizer Inc.
    • 9.9.1. Company Overview
    • 9.9.2. Company Snapshot
    • 9.9.3. Financial Overview
    • 9.9.4. Product Listing
    • 9.9.5. Entropy
  • 9.10. AstraZeneca
    • 9.10.1. Company Overview
    • 9.10.2. Company Snapshot
    • 9.10.3. Financial Overview
    • 9.10.4 Product Listing
    • 9.10.5. Entropy
  • 9.11. Bristol Myers Squibbs
    • 9.11.1. Company Overview
    • 9.11.2. Company Snapshot
    • 9.11.3. Financial Overview
    • 9.11.4. Product Listing
    • 9.11.5. Entropy
  • 9.12. Gilead Sciences, Inc.
    • 9.12.1. Company Overview
    • 9.12.2. Company Snapshot
    • 9.12.3. Financial Overview
    • 9.12.4. Product Listing
    • 9.12.5. Entropy
  • 9.13. Janssen Global Services, LLC
    • 9.13.1. Company Overview
    • 9.13.2. Company Snapshot
    • 9.13.3. Financial Overview
    • 9.13.4. Product Listing
    • 9.13.5. Entropy
  • 9.14. BAYER AG
    • 9.14.1. Company Overview
    • 9.14.2. Company Snapshot
    • 9.14.3. Financial Overview
    • 9.14.4. Product Listing
    • 9.14.5. Entropy
  • 9.15. Celldex Therapeutics Inc
    • 9.15.1. Company Overview
    • 9.15.2. Company Snapshot
    • 9.15.3. Financial Overview
    • 9.15.4. Product Listing
    • 9.15.5. Entropy
  • 9.16. Alaunos Therapeutics, Inc.,
    • 9.16.1. Company Overview
    • 9.16.2. Company Snapshot
    • 9.16.3. Financial Overview
    • 9.16.4. Product Listing
    • 9.16.5. Entropy
  • 9.17. Astellas Pharma Inc
    • 9.17.1. Company Overview
    • 9.17.2. Company Snapshot
    • 9.17.3. Financial Overview
    • 9.17.4. Product Listing
    • 9.17.5. Entropy
  • 9.18. Genentech Inc
    • 9.18.1. Company Overview
    • 9.18.2. Company Snapshot
    • 9.18.3. Financial Overview
    • 9.18.4. Product Listing
    • 9.18.5. Entropy
  • 9.19. Sandoz International GmbH
    • 9.19.1. Company Overview
    • 9.19.2. Company Snapshot
    • 9.19.3. Financial Overview
    • 9.19.4. Product Listing
    • 9.19.5. Entropy
  • 9.20. BeiGene
    • 9.20.1. Company Overview
    • 9.20.2. Company Snapshot
    • 9.20.3. Financial Overview
    • 9.20.4. Product Listing
    • 9.20.5. Entropy

10. KOL Views

11. Project Approach

12. About DelveInsight

13. Disclaimer & Contact Us